WP
OTLK icon

Woodline Partners’s Outlook Therapeutics OTLK Stock Holding History

Woodline Partners’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-151,508
Closed -$286K – 999
2024
Q4 		$286K Hold
151,508
– – ﹤0.01% 892
2024
Q3 		$809K Buy
151,508
+722
+0.5% +$5.28K 0.01% 519
2024
Q2 		$1.11M Buy
+150,786
New +$1.21M 0.01% 455

Other funds holding OTLK

SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Woodline Partners's OTLK Position: Q1 2025 in Review

Woodline Partners sold out of Outlook Therapeutics (OTLK) in Q1 2025, closing a stake of 151,508 shares — an estimated $286K sold.

Woodline Partners first reported a position in OTLK in Q2 2024 and held it in 3 quarters. The position peaked at $1.11M in Q2 2024. 63 funds tracked by Wall St. Rank hold OTLK as of Q1 2025.

  • Woodline Partners reported no remaining Outlook Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Woodline Partners sold 151,508 Outlook Therapeutics shares in Q1 2025, an estimated $286K.
  • Woodline Partners first reported a position in Outlook Therapeutics in Q2 2024 and held it in 3 quarters.
  • Woodline Partners's Outlook Therapeutics position peaked at $1.11M in Q2 2024.
  • 63 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2025.

Based on Woodline Partners's 13F filing for Q1 2025, filed 15 May 2025.